What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Prostate cancer, Internal medicine, Cancer biomarkers, Oncology and Cancer research are his primary areas of study.
The study incorporates disciplines such as Prostate and Docetaxel in addition to Prostate cancer.
His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Surgery.
His Cancer biomarkers research includes themes of Androgen Receptor Antagonists, Disease, Immunology and Circulating tumor cell.
His Oncology research integrates issues from Neoplasm, Androgen deprivation therapy and Phases of clinical research.
His Cancer research research is multidisciplinary, relying on both Cancer and Pathology.
His most cited work include:
- Integrative clinical genomics of advanced prostate cancer (1675 citations)
- Integrative clinical genomics of advanced prostate cancer (1675 citations)
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. (1142 citations)
What are the main themes of his work throughout his whole career to date?
Gerhardt Attard mostly deals with Prostate cancer, Internal medicine, Oncology, Cancer biomarkers and Abiraterone acetate.
His study focuses on the intersection of Prostate cancer and fields such as Cancer research with connections in the field of Prostate, PTEN and Mutation.
His research ties Endocrinology and Internal medicine together.
His Oncology study combines topics in areas such as Abiraterone, Circulating tumor cell, Androgen deprivation therapy, Proportional hazards model and Biomarker.
Gerhardt Attard has included themes like Clinical trial, Bioinformatics and Pathology in his Cancer biomarkers study.
In Abiraterone acetate, Gerhardt Attard works on issues like Pharmacology, which are connected to CYP17A1 Inhibitor.
He most often published in these fields:
- Prostate cancer (94.83%)
- Internal medicine (75.99%)
- Oncology (60.18%)
What were the highlights of his more recent work (between 2017-2021)?
- Prostate cancer (94.83%)
- Internal medicine (75.99%)
- Oncology (60.18%)
In recent papers he was focusing on the following fields of study:
Gerhardt Attard mainly focuses on Prostate cancer, Internal medicine, Oncology, Androgen receptor and Enzalutamide.
Gerhardt Attard interconnects Taxane, Cancer research and Prednisone in the investigation of issues within Prostate cancer.
Gerhardt Attard works mostly in the field of Cancer research, limiting it down to topics relating to Prostate and, in certain cases, Immune system and Metastasis, as a part of the same area of interest.
His Internal medicine and Hazard ratio, Confidence interval, Clinical trial, Apalutamide and Abiraterone investigations all form part of his Internal medicine research activities.
His Oncology research is multidisciplinary, incorporating elements of Chemotherapy, Docetaxel, Androgen deprivation therapy, Biomarker and Radiation therapy.
The concepts of his Abiraterone acetate study are interwoven with issues in Double blind study and Poly ADP ribose polymerase.
Between 2017 and 2021, his most popular works were:
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. (375 citations)
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 (333 citations)
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer (108 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Hazard ratio and Enzalutamide.
His studies in Prostate cancer integrate themes in fields like Evidence synthesis and Cancer research.
His research on Internal medicine often connects related topics like Gastroenterology.
The various areas that Gerhardt Attard examines in his Oncology study include Androgen deprivation therapy, Hormone sensitive prostate cancer and Docetaxel.
His research investigates the connection between Androgen receptor and topics such as Taxane that intersect with problems in Circulating tumor cell and Blood test.
His Randomized controlled trial study which covers Clinical trial that intersects with Visual analogue scale, Placebo, Cancer biomarkers and Metastasis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
